Developmental funds controlled by the Director are derive from institutional sources, including Knight Cancer Institute funds raised through the OHSU Foundation, contributions from the OHSU Hospital and Clinics and the School of Medicine, and the support from our CCSG. The Director has formal authority for all cancer related funds raised by the OHSU Foundation. The Knight Cancer Institute has used developmental funds from philanthropic sources as well as CCSG support to: recruit new faculty, support pilot projects, establish new Shared Resources, and provide support for technological and resource enhancements within the Shared Resources. In the last funding period, the OHSU development staff raised $33,000,000 in philanthropic contributions with an additional $98,000,000 gift that will be distributed over the next 5 - 7 years. Additionally, three endowed faculty positions have been established. The Knight has used CCSG funds, matched with philanthropic funds to support pilot projects, career development awards and bridge funding. The goal of this support has been to provide critical resources for cancer investigators to obtain preliminary funding for external peer-reviewed funding and to encourage innovative cancer research projects. A total of $668,000 of pilot project and career development award funding have been distributed over the past five years. These funds have contributed to over $20.9 million of external peer-reviewed funding. Development funds have been utilized to strengthen shared resources, as well as support women accruals to clinical trials. Over the past funding period shared resources have been invested in heavily to expand services offered, upgrade instrumentation, and ensure that sen/ices offered remain state-of-the art. To support accrual of women to clinical trials, funds were spent for recruitment of faculty specializing in female oncologic diseases, and infrastructure support for the Clinical Research Management Shared Resource.
The Knight Cancer Institute has used developmental funds from philanthropic sources as well as CCSG support to: recruit new faculty, support pilot projects, establish new Shared Resources, and provide support for technological and resource enhancements within the Shared Resources.
|Farrell, Amy S; Joly, Meghan Morrison; Allen-Petersen, Brittany L et al. (2017) MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun 8:1728|
|De Maria, Alicia; Wilmarth, Phillip A; David, Larry L et al. (2017) Proteomic Analysis of the Bovine and Human Ciliary Zonule. Invest Ophthalmol Vis Sci 58:573-585|
|Danelishvili, Lia; Chinison, Jessica J J; Pham, Tuan et al. (2017) The Voltage-Dependent Anion Channels (VDAC) of Mycobacterium avium phagosome are associated with bacterial survival and lipid export in macrophages. Sci Rep 7:7007|
|Avenarius, Matthew R; Krey, Jocelyn F; Dumont, Rachel A et al. (2017) Heterodimeric capping protein is required for stereocilia length and width regulation. J Cell Biol 216:3861-3881|
|Cassidy, Pamela B; Liu, Tong; Florell, Scott R et al. (2017) A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila) 10:36-44|
|Tsujikawa, Takahiro; Kumar, Sushil; Borkar, Rohan N et al. (2017) Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Rep 19:203-217|
|Kwon, Sunjong; Chin, Koei; Nederlof, Michel et al. (2017) Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution. Sci Rep 7:16459|
|Midgett, Madeline; López, Claudia S; David, Larry et al. (2017) Increased Hemodynamic Load in Early Embryonic Stages Alters Endocardial to Mesenchymal Transition. Front Physiol 8:56|
|Krey, J F; Wilmarth, P A; David, L L et al. (2017) Analysis of the Proteome of Hair-Cell Stereocilia by Mass Spectrometry. Methods Enzymol 585:329-354|
|Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134|
Showing the most recent 10 out of 248 publications